Skip to main content

HEALTH

  • Mylan, Biocon enter deal on generic analog insulins

    PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

    Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

  • Pharmavite expands Voots into Walgreens

    NORTHRIDGE, Calif. — Pharmavite on Tuesday announced that its Voots Veggie-Fruit Tarts brand, a fruit- and vegetable-based supplement for kids ages 4 years and older, are now available for purchase at Walgreens locations nationwide.

  • Reports: Insurers, employers support YMCA diabetes program

    NEW YORK — The YMCA is sponsoring a diabetes-control program that some say could slow the disease's spread, according to published reports.

  • FDA approves Aurobindo diabetes drug

    HYDERABAD, India — The Food and Drug Administration has approved a generic diabetes drug made by Aurobindo Pharma, the drug maker said.

    Aurobindo announced the approval of pioglitazone tablets in the 15 mg, 30 mg and 45 mg strengths, in addition to the earlier tentative approval it received for pioglitazone and metformin hydrochloride tablets in the 15 mg/500 mg and 15 mg/850 mg strengths.

  • FDA seizes tainted product from Florida's Globe All Wellness

    SILVER SPRING, Md. — U.S. marshals, acting on behalf of the Food and Drug Administration, on Thursday seized tainted products from Globe All Wellness in Hollywood, Fla. The products may be unsafe because they contain an undisclosed active pharmaceutical ingredient.

  • GNC raises $3.1 million for St. Jude Children's Research Hospital

    PITTSBURGH — GNC on Friday announced that its employees and customers donated a total of $3.1 million over the past few months to support the St. Jude Children's Research Hospital Thanks and Giving campaign. The campaign, now in its ninth year, builds awareness of and raises funds for the research and treatment done at St. Jude to help children fighting cancer. 

  • GAO issues report on the impact PSE sales restrictions have on meth labs

    WASHINGTON — According to a report filed to Congress by the Government Accountability Office on Wednesday, the seizures of methamphetamine-producing labs declined following state and federal sales restrictions on pseudoephedrine. And while electronic tracking systems help enforce PSE sales limits, those efforts have not reduced meth lab incidents and have limitations related to smurfing, the GAO added. 

X
This ad will auto-close in 10 seconds